Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02386709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer

Study acronym: TREN
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 25, 2023 to Mar 25, 2028 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv8 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  2. Primary completion date: Mar 25, 2015 to Mar 25, 2023 Completion date: Mar 25, 2021 to Mar 25, 2028 · Study arms: 0 to 1v7 Show 2 more changesShow less
    • Completion date: Mar 25, 2021 to Mar 25, 2028
    • Study arms: 0 to 1
  3. Completion date: Mar 25, 2020 to Mar 25, 2021v6
  4. Primary completion date changed from estimate of Mar 2020 to Mar 25, 2015 Completion date: Mar 2025 to Mar 25, 2020 · Start date: Mar 2015 to Mar 25, 2015v5 Show 2 more changesShow less
    • Completion date: Mar 2025 to Mar 25, 2020
    • Start date: Mar 2015 to Mar 25, 2015
  5. Completion date: Mar 2025v4
Show 2 earlier versionsHide 2 earlier versions
  1. Study site revisedv3 See this version in full on ClinicalTrials.gov ↗
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Neoadjuvant chemotherapy is frequently proposed to patients with mammary gland cancer. The aim is to reduce tumor volume before surgical therapy. Obtaining a pathologic Complete Response (pCR) is regarded as a good prognostic factor with less risk of recurrence. The rate of pCR is about 20%, although there are important variations according to tumor subtype and the type of treatment. The objective of the new therapeutic strategies is to increase this response rate. The purpose of this study is to investigate the possibility of early evaluation of neoadjuvant chemotherapy response after one cycle of neoadjuvant chemotherapy by positron emission tomography (PET) with (18) F-fluorodeoxyglucose (FDG) in patients.
Trial Details
NCT Number NCT02386709
Lead Sponsor Centre Georges Francois Leclerc
Conditions FDG PET
Enrollment 275 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov